Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)
Post# of 721
(Total Views: 299)
Posted On: 07/18/2017 4:43:39 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Well-positioned For Expanding Canadian Cannabinoid Market
Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market
Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020
Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system
Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids.
With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.
While cannabinoids such as cannabidiol (CBD) and THC boast a wide range of health benefits, they are poorly absorbed by the human gastrointestinal tract. Lexaria’s products take advantage of the company’s patented technology to offer health-conscious consumers improved absorption and taste of orally-ingested products. Lexaria’s lipophilic enhancement technology is proven to enhance the bioavailability of orally-ingested cannabinoids, thus allowing for lower dosages.
The company is in discussions for or has already signed B2B agreements with companies in Canada, the largest-market states in the U.S., and internationally. Lexaria has also developed its own brands using its patented technology to infuse hemp oil ingredients within lipids in foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.
Lexaria continues research and development, signing a collaborative research agreement with the National Research Council of Canada (NRC) in February 2017 to investigate new opportunities in bioavailability enhancement of lipophilic active ingredient compositions. The company believes its patented technology can be utilized for the delivery of nicotine, vitamins, analgesics and a variety of other substances.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market
Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020
Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system
Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids.
With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.
While cannabinoids such as cannabidiol (CBD) and THC boast a wide range of health benefits, they are poorly absorbed by the human gastrointestinal tract. Lexaria’s products take advantage of the company’s patented technology to offer health-conscious consumers improved absorption and taste of orally-ingested products. Lexaria’s lipophilic enhancement technology is proven to enhance the bioavailability of orally-ingested cannabinoids, thus allowing for lower dosages.
The company is in discussions for or has already signed B2B agreements with companies in Canada, the largest-market states in the U.S., and internationally. Lexaria has also developed its own brands using its patented technology to infuse hemp oil ingredients within lipids in foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.
Lexaria continues research and development, signing a collaborative research agreement with the National Research Council of Canada (NRC) in February 2017 to investigate new opportunities in bioavailability enhancement of lipophilic active ingredient compositions. The company believes its patented technology can be utilized for the delivery of nicotine, vitamins, analgesics and a variety of other substances.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)